Filing Details

Accession Number:
0001127602-10-007276
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-03-03 12:00:00
Reporting Period:
2010-03-01
Filing Date:
2010-03-03
Accepted Time:
2010-03-03 18:08:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1097264 Allos Therapeutics Inc ALTH Pharmaceutical Preparations (2834) 541655029
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1202770 V James Caruso 11080 Circlepoint Road
Suite 200
Westminster CO 80020
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-03-01 40,000 $3.13 181,159 No 4 M Direct
Common Stock Disposition 2010-03-01 40,000 $8.13 141,159 No 4 S Direct
Common Stock Disposition 2010-03-01 37,500 $8.13 103,659 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Disposition 2010-03-01 40,000 $0.00 40,000 $3.13
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
60,000 2007-06-05 2016-06-05 No 4 M Direct
Footnotes
  1. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan under which Mr. Caruso sold a portion of his holdings for tax and estate planning purposes.
  2. The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $8.13 to $8.14. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
  3. Stock options vest according to the following schedule: One fourth (1/4) of the total number of shares subject to this option shall vest 12 months after the vesting commencement date and an additional one-forty-eigths (1/48) of the total number of shares subject to the option become exercisable each one-month-period thereafter, until all such shares are exercisable.